d202 - rDer p 1 (Dermatophagoides pteronyssinus)
Test details
This test is useful when a dust mite allergy is suspected and to identify the specific molecule that has previously caused a positive result in the associated allergen extract test.
Der p 1 is a cysteine protease located in the gut and in faecal particles of house dust mites. The prevalence of this molecule exceeds 70% among patients sensitised to Dermatophagoides pteronyssinus. Exposure to Der p 1 occurs through inhalation of mite faeces. Symptoms associated with an allergy to this molecule include, primarily, allergic rhinitis, conjunctivitis and coughing due to an itchy throat. In some cases, the allergy may cause skin symptoms and lead to bronchial asthma. There is a high degree of cross-reactivity with the Dermatophagoides farinae Der f 1 molecule. The assessment of sensitisations to Der p 1 is considered important for selecting patients eligible for allergen-specific immunotherapy (AIT).
Sample type
Serum
Method
ChLIA
Preparation
Fasting for at least 8-12 hours before sampling
Storage conditions
Refer to the Health Service Charter to check storage conditions
Shipping
+2/+8°C
References
Hamilton RG. Allergic sensitization is a key risk factor for but not synonymous with allergic disease. J Allergy Clin Immunol. 2014 Aug;134(2):360-1. doi: 10.1016/j.jaci.2014.02.022. Epub 2014 Mar 31. PMID: 24698318.
Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, Valenta R, Hilger C, et al. EAACI Molecular Allergology User's Guide. Pediatr Allergy Immunol. 2016 May;27 Suppl 23:1-250. doi: 10.1111/pai.12563. PMID: 27288833.
laboratory analysis
Find other tests
Total tau
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
Phosphorylated Tau (pTau181)
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Anti–NMDAR Antibodies
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Discover what’s new
Subscribe to the newsletter
Subscribe to our newsletter to be always updated.